2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Multiple Myeloma
251
Lymphoma
128
Leukemia, Myeloid, Acute
103
Lymphoma, Non-Hodgkin
98
Precursor Cell Lymphoblastic Leukemia-Lymphoma
93
Neoplasms, Plasma Cell
91
Myelodysplastic Syndromes
91
Leukemia
79
Hodgkin Disease
78
Lymphoma, Large B-Cell, Diffuse
66
Leukemia, Lymphocytic, Chronic, B-Cell
65
Lymphoma, Mantle-Cell
59
Lymphoma, Follicular
57
Neuroblastoma
44
Burkitt Lymphoma
44
Lymphoma, Large-Cell, Immunoblastic
40
Lymphoma, B-Cell, Marginal Zone
37
Recurrence
34
Myeloproliferative Disorders
32
Hematologic Neoplasms
32
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
30
Immunoglobulin Light-chain Amyloidosis
29
Leukemia, Myeloid, Accelerated Phase
25
Leukemia, Myeloid, Chronic-Phase
24
Congenital Abnormalities
24
Leukemia, Myelomonocytic, Chronic
23
Graft vs Host Disease
23
Dendritic Cell Sarcoma, Interdigitating
21
Waldenstrom Macroglobulinemia
20
Melanoma
20
Interventions
Melphalan
1
Lenograstim
1
1-(1-((5-methoxy-1H-indol-2-yl)carbonyl)piperidin-4-yl)-2-methylpropan-2-ol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Castrate Resistant Prostate Cancer
×
Melphalan
×
Clear all
NCT01907009
2023-04-19
MEL-CAP
Barts & The London NHS Trust
Phase 2/3
Terminated
29 enrolled